What is WHO TRS 1010 and why it matters:

WHO Technical Report Series No. 1010 outlines international expectations for the design, execution, and documentation of pharmaceutical stability studies. It builds on ICH Q1A(R2) and provides additional context for markets in developing countries, tropical zones, and WHO-prequalified product categories.

Aligning with TRS 1010 ensures your stability program satisfies global health authority expectations—particularly for submissions to WHO, low- and middle-income countries (LMICs), and global procurement agencies.

Benefits of TRS 1010 alignment:

Following WHO TRS 1010 supports unified protocol design, facilitates faster WHO prequalification, and reduces post-submission queries. It enables streamlined submissions to countries that use WHO guidance for regulatory evaluation, especially in Zones III and IV (hot and humid conditions).

This alignment promotes universal GMP credibility and enhances your dossier’s global acceptability.

Regulatory and Technical Context:

Key requirements under WHO TRS 1010:

WHO TRS 1010 recommends:

• Long-term testing at 30°C/75% RH for Zone IVb markets
• Use of at least three primary batches in stability studies
• Inclusion of all relevant dosage forms and packaging systems
• Testing at 0, 3, 6, 9, 12, 18, and 24 months minimum
• Complete reporting of physical, chemical, microbiological, and functional attributes

Additional emphasis is placed on climatic zone-specific protocols and clear labeling guidance linked to real data.

CTD alignment and dossier submission implications:

Stability data presented in CTD Module 3.2.P.8.1 and 3.2.P.8.3 must reflect TRS 1010-compliant protocols for WHO-reviewed applications. Agencies that follow WHO guidance (e.g., Tanzania FDA, Nigeria NAFDAC, and ASEAN countries) expect the same format and data rigor. Non-compliance can result in prolonged review cycles or outright rejection.

Best Practices and Implementation:

Design protocols around WHO expectations from the outset:

When planning global registration or WHO prequalification, start with TRS 1010-based parameters. Use climate-appropriate conditions for the target market, and include relevant dosage forms (e.g., oral, parenteral, topical) under real-time and accelerated studies.

Build your testing plan to cover both product and packaging variations, using batch sizes that reflect production scale where feasible.

Document and justify all design decisions:

Include a rationale for your storage conditions, time points, analytical methods, and sampling plan in your protocol. Justify any deviations from WHO expectations—such as omission of intermediate storage or reduced testing frequency—based on product risk and prior data.

Ensure your final study reports clearly label results by condition, batch, and testing period, aligned with the TRS 1010 structure.

Prepare QA and regulatory teams for audits and submissions:

Train cross-functional teams on WHO-specific requirements. Include mock audits using WHO PQ templates, and ensure traceability of all stability data and chain of custody. Highlight WHO-aligned studies in Module 1 of the CTD and flag any supporting literature or cross-referenced data.

Use a centralized data archive for streamlined dossier compilation, variation submissions, and renewals tied to WHO PQ or global tenders.